Cardiology

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Your daily dose of the clinical news you may have missed.

The study found that although PREVENT-generated risk estimates were more consistent in a broad population, PCE estimates were more accurate in those taking statins.

Your daily dose of the clinical news you may have missed.

Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.